


**QUARTERLY COMPLIANCE REPORT ON CORPORATE GOVERNANCE**

**Name of the Company** : ASTRAZENECA PHARMA INDIA LIMITED  
**Scrp Code** : BgSE: ASTRAZEN / BSE: 506820 / NSE: ASTRAZEN  
**Quarter ending on** : December 31, 2012

Particulars	Clause of Listing agreement	Compliance Status Yes/No	Remarks
<b>I. Board of Directors</b>	49 (I)		
(A) Composition of Board	49 (IA)	Yes	
(B) Non-executive Directors' compensation & disclosures	49 (IB)	Yes	Disclosed in the Annual Report for the year ended March 31, 2012
(C) Other provisions as to Board and Committees	49 (IC)	Yes	
(D) Code of Conduct	49 (ID)	Yes	
<b>II. Audit Committee</b>	49 (II)		
(A) Qualified & Independent Audit Committee	49 (IIA)	Yes	
(B) Meeting of Audit Committee	49 (IIB)	Yes	
(C) Powers of Audit Committee	49 (IIC)	Yes	
(D) Role of Audit Committee	49 II(D)	Yes	
(E) Review of Information by Audit Committee	49 (IIE)	Yes	
<b>III. Subsidiary Companies</b>	49 (III)	NA	There is no subsidiary
<b>IV. Disclosures</b>	49 (IV)		
(A) Basis of related party transactions	49 (IV A)	Yes	
(B) Disclosure of Accounting Treatment	49 (IV B)	Yes	
(C) Board Disclosures	49 (IV C)	Yes	
(D) Proceeds from public issues, rights issues, preferential issues etc.	49 (IV D)	NA	No proceeds from public issues, rights issue, preferential issues etc.
(E) Remuneration of Directors	49 (IV E)	Yes	Disclosed in the Annual Report for the year ended March 31, 2012
(F) Management	49 (IV F)	Yes	Disclosed in the Annual Report for the year ended March 31, 2012
(G) Shareholders	49 (IV G)	Yes	Disclosed in the Annual Report for the year ended March 31, 2012
<b>V. CEO/CFO Certification</b>	49 (V)	Yes	Disclosed in the Annual Report for the year ended March 31, 2012
<b>VI. Report on Corporate Governance</b>	49 (VI)	Yes	Disclosed in the Annual Report for the year ended March 31, 2012
<b>VII. Compliance</b>	49 (VII)	Yes	Disclosed in the Annual Report for the year ended March 31, 2012

For AstraZeneca Pharma India Limited

  
Pawan Singhal  
Vice President-Legal & Company Secretary